But for some Indian start-ups such as Uniphore having Amazon, Apple and Google in their space has worked well for them. Uniphore provides speech analytics, a virtual assistant and portable voice biometric system for its enterprise clients. “Since Amazon, Apple and Google are making significant investments in speech recognition, it brings a lot of awareness to the space. A lot of enterprises are now looking to add a voice layer to their applications. Enterprises usually follow where consumers go,” says Umesh Sachdev, CEO, Uniphore. He believes all the efforts of the biggies in the area of speech recognition have opened up a $450 billion-$500 billion enterprise market for Uniphore. “We can disrupt the entire call centre industry with our solutions,” he says. Uniphore counts Cisco’s chairman John Chambers, Kris Gopalakrishnan and IDG Ventures among its investors and is one of the earliest start-ups in India to build a deep tech model in speech recognition. “It is all moving from touch to speech,” says Sateesh Andra, managing director, Endiya Partners. “Indian start-ups will do well if they are able to use the technology to solve an existing problem. They can leverage AI not only to build applications for the local market but can also take the product global.” He gives the example of his portfolio company SigTuple, which is addressing a global problem — a shortage of pathologists — with its AI solution. India has one pathologist per 65,000 people and in China, the number is worse with one pathologist for every 130,000. Even in the US there are only 5.8 pathologists for every 100,000. A shortage of pathologists means you have an overworked pathologist or a half-baked technician analysing the slides and there is a good chance they could miss something during diagnosis. SigTuple has developed a low-cost machine that digitises blood and pathology samples by attaching smartphone and mechanical components to a regular microscope. The AI software automatically scans and analyses blood smears as well as other biological samples, tags the visual data and churns out the results in minutes. It also provides visual evidence to easily verify the result. Since it is addressing a larger problem across countries, the company plans to go global and is planning to work towards an USFDA approval.